CDMO’s new facility is expected to be operational by April 2025.
Samsung Biologics, a contract development and manufacturing organization (CDMO) plans to have its new fifth plant operational by April 2025. Earlier this month, the company fully completed its latest biomanufacturing plant, Plant 4.
As the first facility of Samsung Biologics’ second Bio Campus at its headquarters in Songdo, South Korea, Plant 5 is expected to have a construction timeline of 24 months. It will add a capacity of 180,000 liters, featuring process integration and optimization, as well as advanced automation. The new plant will also feature sustainable systems to support the company’s commitment in achieving net zero greenhouse gas emissions by 2050 or earlier.
